急性髓系白血病的靶向治疗药物研发进展  

Progress in Development of Targeted Therapeutic Drugs for Acute Myeloid Leukemia

作　　者：季晓君 赵廷丽 苗雷 司亚璇 吴舰 徐丹 JI Xiaojun;ZHAO Tingli;MIAO Lei;SI Yaxuan;WU Jian;XU Dan(Innovation Department of the Research Institute,Nanjing Chia Tai Tian Qing Pharmaceutical Co.,Ltd,Nanjing 210046,China)

机构地区：[1]南京正大天晴制药有限公司研究院创新所,南京210046

出　　处：《肿瘤防治研究》2023年第4期413-421,共9页Cancer Research on Prevention and Treatment

摘　　要：在过去的十年里,急性髓系白血病(AML)的靶向治疗药物研发呈现出井喷式的势头,为AML患者的精准治疗奠定了坚实的基础。本文综述了近期在AML治疗领域进展较快的4类靶向药物(靶向基因或信号通路改变、靶向细胞凋亡相关通路、靶向细胞表面抗原以及靶向免疫相关靶点),并展望了未来靶向药物的开发方向,为血液科医师和AML新药开发人员提供参考。Targeted therapeutic drugs for acute myeloid leukemia(AML)are showing immense development,thereby laying a solid foundation for the precise treatment of AML patients.The paper reviews four types of targeted drugs that have progressed rapidly for AML treatment(by targeting genes or signaling-pathway alterations,targeting apoptosis-related pathways,targeting cell-surface antigens,and targeting immune-related substances).We look forward to the future development directions of targeted drugs,providing references for hematologists and developers of new drugs for AML.

关 键 词：急性髓系白血病 靶向治疗 免疫治疗 药物进展 

分 类 号：R733.71[医药卫生—肿瘤]